# Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
Canonical URL: https://biopharmsignal.com/news/CADL/candel-therapeutics-appoints-mark-sims-as-chief-commercial-officer
Ticker: CADL
Company: Candel Therapeutics
Source: Candel Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.candeltx.com
## Summary

Appointment supports planned Biologics License Application (BLA) submission in the fourth quarter of 2026 and potential 2027 launch of aglatimagene besadenovec in localized prostate cancer NEEDHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc.

## Article Body
Appointment supports planned Biologics License Application (BLA) submission in the fourth quarter of 2026 and potential 2027 launch of aglatimagene besadenovec in localized prostate cancer NEEDHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc.
## Recent Company News
- 2026-07-01 08:05 EST — [Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/CADL/candel-therapeutics-announces-inducement-grants-under-nasdaq-4) — Source: Candel Therapeutics
- 2026-06-30 00:05 EST — [Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors](https://biopharmsignal.com/news/CADL/candel-therapeutics-announces-initiation-global-pivotal-phase-3) — Source: Candel Therapeutics
- 2026-06-25 13:46 EST — [Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer](https://biopharmsignal.com/news/CADL/candel-therapeutics-appoints-mark-sims-as-chief-commercial-officer) — Source: Candel Therapeutics
- 2026-06-25 13:46 EST — [Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer](https://biopharmsignal.com/news/CADL/candel-therapeutics-announces-publication-in-the-lancet-oncology-of-pivotal-phase-3-data-demonstrating-significant-improvement-in-disease-free-survival-with-aglatimagene-besadenovec-can-2409-in-localized-prostate-cancer) — Source: Candel Therapeutics
- 2026-06-25 13:46 EST — [Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting](https://biopharmsignal.com/news/CADL/candel-therapeutics-reports-extended-clinical-benefit-over-multiple-clinical-endpoints-in-patients-from-phase-3-trial-of-aglatimagene-besadenovec-can-2409-in-localized-prostate-cancer-under-prolonged-follow-up-at-aua-2026-annual-meeting) — Source: Candel Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)